Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Hum Pathol. 2011 Dec;42(12):1946-52. doi: 10.1016/j.humpath.2011.02.017. Epub 2011 Jun 17.
Activated leukocyte cell adhesion molecule (CD166) is a member of the immunoglobulin superfamily and is aberrantly expressed in different tumors, including prostate cancer. To learn more on the prevalence and clinical significance of activated leukocyte cell adhesion molecule expression in prostate cancer, a tissue microarray containing 3261 primary prostate cancers treated by radical prostatectomy was used. A total of 2390 different prostate cancers were analyzed by immunohistochemistry in a tissue microarray format. Activated leukocyte cell adhesion molecule immunostaining in cancers was compared with clinical follow-up, which was available for 1746 patients. Membranous activated leukocyte cell adhesion molecule immunostaining was recorded in 1663 (69.6%) of cases. High activated leukocyte cell adhesion molecule expression levels were significantly associated with favorable tumor features (pT: P = .0015; pN: P = .0008; preoperative prostate-specific antigen: P = .0057) and a lower risk of a biochemical recurrence (P = .0067). Cytoplasmatic activated leukocyte cell adhesion molecule staining was usually associated with membranous staining. The small number of cancers with pure cytoplasmatic staining did not reveal any particularities with respect to clinical outcome or tumor phenotype. It is concluded that activated leukocyte cell adhesion molecule protein is almost always expressed in prostate cancer and that decreased levels of activated leukocyte cell adhesion molecule expression may lead to an aggressive behavior of tumor cells. The abundant presence of activated leukocyte cell adhesion molecule and its membranous localization in prostate cancer epithelium make activated leukocyte cell adhesion molecule a potentially attractive structure for targeted therapy.
激活白细胞细胞黏附分子（CD166）是免疫球蛋白超家族的成员，在包括前列腺癌在内的不同肿瘤中异常表达。为了更多地了解激活白细胞细胞黏附分子在前列腺癌中的表达流行率和临床意义，使用包含 3261 例接受根治性前列腺切除术治疗的原发性前列腺癌的组织微阵列进行了研究。通过组织微阵列格式的免疫组织化学分析了 2390 例不同的前列腺癌。将癌症中的激活白细胞细胞黏附分子免疫染色与临床随访进行了比较，其中 1746 例患者可获得随访结果。在 1663 例（69.6%）病例中记录到膜激活白细胞细胞黏附分子免疫染色。高表达水平的激活白细胞细胞黏附分子与良好的肿瘤特征显著相关（pT：P =.0015；pN：P =.0008；术前前列腺特异性抗原：P =.0057），并且生化复发的风险较低（P =.0067）。细胞质激活白细胞细胞黏附分子染色通常与膜染色相关。具有纯细胞质染色的少数癌症在临床结局或肿瘤表型方面没有表现出任何特殊性。因此可以得出结论，激活白细胞细胞黏附分子蛋白几乎总是在前列腺癌中表达，而激活白细胞细胞黏附分子表达水平降低可能导致肿瘤细胞的侵袭性行为。激活白细胞细胞黏附分子在前列腺癌细胞上皮中的丰富存在及其膜定位使激活白细胞细胞黏附分子成为靶向治疗的潜在有吸引力的结构。
